Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Lancet Oncology Année : 2019

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Fichier principal
Vignette du fichier
S1470204519300828.pdf (298.74 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03484988 , version 1 (20-12-2021)

Licence

Identifiants

Citer

Karim Fizazi, Namphuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, et al.. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology, 2019, 20, pp.686 - 700. ⟨10.1016/S1470-2045(19)30082-8⟩. ⟨hal-03484988⟩
37 Consultations
1241 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More